Foamix is a specialty pharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond.
Company profile
Ticker
FOMX
Exchange
Website
CEO
David Domzalski
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Foamix Ltd.
SEC CIK
Corporate docs
Subsidiaries
Foamix Pharmaceutical Inc. ...
FOMX stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
23 Mar 20
15-12B
Securities registration termination
19 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
POS AM
Prospectus update (post-effective amendment)
18 Mar 20
10-K
2019 FY
Annual report
12 Mar 20
8-K
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended Research and Development Expenses
12 Mar 20
8-K
Entry into a Material Definitive Agreement
10 Mar 20
Transcripts
Institutional ownership, Q3 2021
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|